Berto Acquisition (TACO) Competitors

Berto Acquisition logo
$10.53 +0.01 (+0.10%)
Closing price 03:59 PM Eastern
Extended Trading
$10.52 0.00 (-0.05%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TACO vs. OPK, INNV, OMDA, LMRI, and CSTL

Should you buy Berto Acquisition stock or one of its competitors? Berto Acquisition's main competitors and comparable companies include OPKO Health (OPK), InnovAge (INNV), Omada Health (OMDA), Lumexa Imaging (LMRI), and Castle Biosciences (CSTL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Berto Acquisition compare to OPKO Health?

Berto Acquisition (NASDAQ:TACO) and OPKO Health (NASDAQ:OPK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Berto Acquisition has a net margin of 0.00% compared to OPKO Health's net margin of -29.51%. Berto Acquisition's return on equity of 0.00% beat OPKO Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Berto AcquisitionN/A N/A N/A
OPKO Health -29.51%-10.90%-6.93%

In the previous week, OPKO Health had 4 more articles in the media than Berto Acquisition. MarketBeat recorded 9 mentions for OPKO Health and 5 mentions for Berto Acquisition. Berto Acquisition's average media sentiment score of 0.97 beat OPKO Health's score of 0.44 indicating that Berto Acquisition is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Berto Acquisition
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
OPKO Health
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Berto Acquisition has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

64.6% of OPKO Health shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Berto Acquisition has higher earnings, but lower revenue than OPKO Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Berto AcquisitionN/AN/AN/AN/AN/A
OPKO Health$654.10M1.84-$225.68M-$0.19N/A

OPKO Health has a consensus price target of $3.42, indicating a potential upside of 110.91%. Given OPKO Health's stronger consensus rating and higher possible upside, analysts clearly believe OPKO Health is more favorable than Berto Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Berto Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
OPKO Health
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Summary

OPKO Health beats Berto Acquisition on 8 of the 12 factors compared between the two stocks.

How does Berto Acquisition compare to InnovAge?

InnovAge (NASDAQ:INNV) and Berto Acquisition (NASDAQ:TACO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, InnovAge had 1 more articles in the media than Berto Acquisition. MarketBeat recorded 6 mentions for InnovAge and 5 mentions for Berto Acquisition. Berto Acquisition's average media sentiment score of 0.97 beat InnovAge's score of 0.47 indicating that Berto Acquisition is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InnovAge
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Berto Acquisition
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

InnovAge has a net margin of 0.88% compared to Berto Acquisition's net margin of 0.00%. InnovAge's return on equity of 3.63% beat Berto Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
InnovAge0.88% 3.63% 1.64%
Berto Acquisition N/A N/A N/A

Berto Acquisition has lower revenue, but higher earnings than InnovAge.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovAge$989.71M1.30-$2.54M$0.06157.00
Berto AcquisitionN/AN/AN/AN/AN/A

InnovAge presently has a consensus price target of $10.50, indicating a potential upside of 11.46%. Given InnovAge's stronger consensus rating and higher probable upside, research analysts clearly believe InnovAge is more favorable than Berto Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InnovAge
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Berto Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

InnovAge has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Berto Acquisition has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market.

12.3% of InnovAge shares are held by institutional investors. 1.1% of InnovAge shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

InnovAge beats Berto Acquisition on 11 of the 12 factors compared between the two stocks.

How does Berto Acquisition compare to Omada Health?

Omada Health (NASDAQ:OMDA) and Berto Acquisition (NASDAQ:TACO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Berto Acquisition has lower revenue, but higher earnings than Omada Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omada Health$260.21M3.36-$12.78M$0.2167.05
Berto AcquisitionN/AN/AN/AN/AN/A

Omada Health currently has a consensus target price of $25.92, indicating a potential upside of 84.07%. Given Omada Health's stronger consensus rating and higher possible upside, analysts plainly believe Omada Health is more favorable than Berto Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omada Health
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.67
Berto Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Omada Health had 3 more articles in the media than Berto Acquisition. MarketBeat recorded 8 mentions for Omada Health and 5 mentions for Berto Acquisition. Berto Acquisition's average media sentiment score of 0.97 beat Omada Health's score of 0.01 indicating that Berto Acquisition is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omada Health
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Berto Acquisition
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Omada Health has a net margin of 4.21% compared to Berto Acquisition's net margin of 0.00%. Omada Health's return on equity of 5.71% beat Berto Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Omada Health4.21% 5.71% 4.40%
Berto Acquisition N/A N/A N/A

Omada Health has a beta of 2.13, suggesting that its stock price is 113% more volatile than the broader market. Comparatively, Berto Acquisition has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market.

Summary

Omada Health beats Berto Acquisition on 9 of the 10 factors compared between the two stocks.

How does Berto Acquisition compare to Lumexa Imaging?

Berto Acquisition (NASDAQ:TACO) and Lumexa Imaging (NASDAQ:LMRI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

In the previous week, Lumexa Imaging had 14 more articles in the media than Berto Acquisition. MarketBeat recorded 19 mentions for Lumexa Imaging and 5 mentions for Berto Acquisition. Berto Acquisition's average media sentiment score of 0.97 beat Lumexa Imaging's score of 0.68 indicating that Berto Acquisition is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Berto Acquisition
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lumexa Imaging
5 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lumexa Imaging has a consensus price target of $17.60, suggesting a potential upside of 20.30%. Given Lumexa Imaging's stronger consensus rating and higher probable upside, analysts clearly believe Lumexa Imaging is more favorable than Berto Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Berto Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lumexa Imaging
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
3.00

Berto Acquisition has higher earnings, but lower revenue than Lumexa Imaging.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Berto AcquisitionN/AN/AN/AN/AN/A
Lumexa Imaging$267.73M5.25-$47.10M-$0.54N/A

Berto Acquisition has a net margin of 0.00% compared to Lumexa Imaging's net margin of -1.96%. Berto Acquisition's return on equity of 0.00% beat Lumexa Imaging's return on equity.

Company Net Margins Return on Equity Return on Assets
Berto AcquisitionN/A N/A N/A
Lumexa Imaging -1.96%-2.93%-0.99%

Summary

Lumexa Imaging beats Berto Acquisition on 6 of the 10 factors compared between the two stocks.

How does Berto Acquisition compare to Castle Biosciences?

Castle Biosciences (NASDAQ:CSTL) and Berto Acquisition (NASDAQ:TACO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Castle Biosciences presently has a consensus price target of $46.50, indicating a potential upside of 40.99%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Castle Biosciences is more favorable than Berto Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Castle Biosciences
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Berto Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

92.6% of Castle Biosciences shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Berto Acquisition has lower revenue, but higher earnings than Castle Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Castle Biosciences$344.23M2.95-$24.16M-$0.77N/A
Berto AcquisitionN/AN/AN/AN/AN/A

Castle Biosciences has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Berto Acquisition has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

In the previous week, Castle Biosciences had 13 more articles in the media than Berto Acquisition. MarketBeat recorded 18 mentions for Castle Biosciences and 5 mentions for Berto Acquisition. Berto Acquisition's average media sentiment score of 0.97 beat Castle Biosciences' score of 0.55 indicating that Berto Acquisition is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Castle Biosciences
4 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Berto Acquisition
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Berto Acquisition has a net margin of 0.00% compared to Castle Biosciences' net margin of -6.10%. Berto Acquisition's return on equity of 0.00% beat Castle Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Castle Biosciences-6.10% -4.89% -4.06%
Berto Acquisition N/A N/A N/A

Summary

Castle Biosciences beats Berto Acquisition on 9 of the 13 factors compared between the two stocks.

Get Berto Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for TACO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TACO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TACO vs. The Competition

MetricBerto AcquisitionHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$343.49M$10.57B$7.74B$11.62B
Dividend YieldN/A2.54%2.46%4.43%
P/E RatioN/A35.7734.1629.83
Price / SalesN/A2.088.485.62
Price / CashN/A23.3421.9322.50
Price / BookN/A3.594.373.66
Net IncomeN/A$332.46M$3.52B$392.18M
7 Day Performance0.19%-4.03%-5.43%-4.26%
1 Month Performance0.48%-1.76%-4.54%-6.73%
1 Year Performance3.44%18.97%-1.42%-7.08%

Berto Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TACO
Berto Acquisition
N/A$10.53
+0.1%
N/A+3.3%$343.49MN/AN/A1
OPK
OPKO Health
2.9718 of 5 stars
$1.77
+2.9%
$3.42
+93.0%
+26.6%$1.28B$587.90MN/A1,373
INNV
InnovAge
2.5205 of 5 stars
$9.79
+10.6%
$10.50
+7.3%
+97.9%$1.21B$989.71M147.502,500
OMDA
Omada Health
3.3786 of 5 stars
$19.43
+4.6%
$26.42
+36.0%
-27.7%$1.14B$260.21M232.25946
LMRI
Lumexa Imaging
3.9607 of 5 stars
$13.10
+16.8%
$16.40
+25.2%
N/A$1.08B$267.73MN/A5,019

Related Companies and Tools


This page (NASDAQ:TACO) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners